Preview

Experimental and Clinical Gastroenterology

Advanced search

THE ROLE OF THE MICROBIOTA OF THE GASTROINTESTINAL TRACT IN THE DEVELOPMENT OF DISEASES OF INTERNAL ORGANS

Abstract

Aim of the review. Present at the modern level of the development of medicine information on the role of the microbiota of the gastrointestinal tract in the formation of pathology of internal organs and the prospects for correcting the disturbed microbial balance. It is shown that a change in the gastrointestinal microbiota can be associated with various diseases of the internal organs. The most complex issue that needs to be addressed is to determine the coefficient of participation of the bacterial overgrowth factor and the role of individual microbiota in the development of non-alcoholic fatty liver disease, non-alcoholic pancreatic fatty disease, metabolic syndrome, type 2 diabetes mellitus, which is due to the current insufficiency evidence base. It is necessary to conduct large randomized controlled trials on the role of normal gastrointestinal microbiota in the prevention and treatment of these diseases. It seems promising to improve and introduce new methods for restoring the microbiota of the gastrointestinal tract by creating preparations containing bacteriocines aimed at eradication of the target microorganism and vaccines capable of preventing the infection with pathogenic microorganisms.

About the Authors

A. M. Osadchuk
Federal State Budget Educational Institution of Higher Education “Samara State Medical University” of the Ministry of Health of the Russian Federation
Russian Federation


I. L. Davydkin
Federal State Budget Educational Institution of Higher Education “Samara State Medical University” of the Ministry of Health of the Russian Federation
Russian Federation


T. A. Gricenko
Federal State Budget Educational Institution of Higher Education “Samara State Medical University” of the Ministry of Health of the Russian Federation
Russian Federation


E. A. Lebedeva
Federal State Budget Educational Institution of Higher Education “Samara State Medical University” of the Ministry of Health of the Russian Federation
Russian Federation


A. E. Petrushin
Federal State Budget Educational Institution of Higher Education “Samara State Medical University” of the Ministry of Health of the Russian Federation
Russian Federation


References

1. Qin J., Li R., Raes J., Arumugam M. et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010; 464: 59-65

2. Guinane С.M., Cotter P. D. Role of the gut microbiota in health and chronic gastrointestinal disease: understanding a hidden metabolic organ. Therap Adv Gastroenterol. 2013; 6(4): 295-308

3. Гумаюнова Н. Г. Выявление синдрома избыточного роста бактерий в тонкой кишке при псориатической болезни. Аспирантский вестник Поволжья. 2009; № 3-4: 162-4

4. Осадчук А.М., Давыдкин И. Л., Гриценко Т. А. и соавт. Эзофагиты у лиц, получающих цитостатическую и противоопухолевую терапию. Современное состояние проблемы. Известия Самарского научного центра Российской академии наук. 2015. 17 (2-3). 603-610

5. Yang I., Woltemate S., Piazuelo M. B. et al. Different gastric microbiota compositions in two human populations with high and low gastric cancer risk in Colombia. Sci Rep. 2016; 6: 18594

6. Laniro G., Molina-Infante J., Gasbarrini A. Gastric microbiota. Helicobacter. 2015; 20 (Suppl 1): 68-71

7. Dicksved J., Linberg M., Rosenquist M., et al. Molecular characterization of the stomach microbiota in patients with gastric cancer and in controls. J. Med. Microbiol. 2009; 58 (Pt 4): 509-16

8. Aviles-Jimenes F., Varquez-Jimenes F., Medrano-Guzman R. et al. Stomach microbiota composition varies between patients with non-atrophic gastritis and patients with intestinal type of gastric cancer. Sci Rep. 2014; 4: 4202.

9. Xiao M., Gao Y., Wang Y. Helicobacter species infection may be associated with cholangiocarcinoma. Int J Clin Pract. 2014; 68: 262-70.

10. Malfertheiner P., Megraud F., O. Morain C.A. et al. Management of Helicobacter pylori infection - the Maastricht V/Florence Consensus Report. Gut. 2016; 0: 1-25.

11. Corte C.D., Ferrari F., Villani A., Nobili V. Epidemiology and natural history of NAFLD. J. Med. Biochem. 2015; 34: 13-7.

12. Romero-Gomez M., Zelber-Sagi S., Trenell M. Treatment of NAFLD with diet, physical activity and exercise. J. Hepatol. 2017; 67(4): 829-846.

13. Leung C., Rivera L., Furness J. B., Angus P.W. The role of the gut microbiota in NAFLD. Nat Rev Gastroenterol Hepatol. 2016; 13(7): 412-25.

14. Hoy-Schulz Y.E., Jannat K., Roberts T. et al. Safety and acceptability of Lactobacillus reuteri DSM 17938 and Bifidobacterium longum subspecies infantis 35624 in Bangladeshi infants: a phase I randomized clinical trial. BMC Complement Altern Med. 2016; 16:44.

15. Yilmaz Y., Eren F. Nonalcoholic steatohepatitis and gut microbiota: Future perspectives on probiotics in metabolic liver diseases. Turk J. Gastroenterol. 2017; 28: 327-8.

16. de Medeiros I. C., de Lima J. G. Nonalcoholic fatty pancreas disease as an endogenous alcoholic fatty pancreas disease. Gastroenterol Hepatol Endosk. 2016; 1(2): 32-39.

17. Голубева Т.И., Трошина И. А., Медведева И. В. Неалкогольная жировая болезнь поджелудочной железы у пациентов с ожирением и метаболическим синдромом. Университетская медицина Урала. 2017; 2 (9): 50-52.

18. Симерзин В. В. Фатенков О. В. Гаглоева И. В. и соавт. Инновации в диагностике и лечении пациентов с гипертриглицеридемиями. Наука и инновации в медицине. 2017; 1(5): 43-51

19. Осадчук A.M., Осадчук М. А., Кветной И. М. Синдром раздраженного кишечника. Клиническая медицина. 2007; 85(3): 46-50

20. Осадчук М.А., Осадчук М. М. Синдром раздраженного кишечника и микробиота: пути оптимизации терапии. Врач. 2015; 5: 47-51

21. Ghoshal U.C., Shukla R., Ghoshal U. et al. The gut microbiota and irritable bowel syndrome: friend or foe? Int J Inflam. 2012; 2012:151085

22. Stojanovic-Stojanovic M., Biagi E., Heilig H. et al. Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology. 2011; 141: 1792-1801

23. Saulnier D., Riehle K., Mistretta T. et al. Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome. Gastroenterology. 2011. 141: 1782-1791

24. Комаров Ф.И., Осадчук А. М., Осадчук М. А., Кветной И. М. Неспецифический язвенный колит. - М.: МИА. - 2008. - 256 с

25. Давыдова О.Е., Каторкин С. Е., Лямин А. В., Андреев П. С. Улучшение результатов лечения пациентов с язвенным колитом с использованием индивидуальных схем эрадикационной терапии условно-патогенной микрофлоры, основанной на микробиологическом мониторинге. Врач-аспирант. 2016; 77(4); 49-55

26. Li Q., Wang C., Tang C., Li N., Li J. Molecular-phylogenetic characterization of the microbiota in ulcerated and non-ulcerated regions in the patients with Crohn’s disease. PLoS One. 2012; 7: e34939

27. Barbut F. Managing antibiotic associated diarrhea. BMJ. 2002; 324 (7350): 1345-1346.

28. McCoy A., Araujo-Perez F., Azcarate-Peril A. et al. Fusobacterium is associated with colorectal adenomas. PLoS One. 2013; 8(1): e53653.

29. Arthur J., Perez-Chanona E., Muhlbauer M. et al. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science. 2012; 338: 120-123.

30. Turnbaugh P., Ridaura V., Faith J. et al. The effect of diet on the human gut microbiome: a metagenomic analysis in humanized gnotobiotic mice. Sci Transl Med. 2009; Nov 11; 1(6): 6ra14.

31. Qin J., Li Y., Cai Z. et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012; 490: 55-60.

32. Andreasen A., Larsen N., Pedersen-Skovsgaard T. et al. Effects of Lactobacillus acidophilus NCFM on insulin sensitivity and the systemic inflammatory response in human subjects. Br J Nutr. 2010; Dec; 104(12):1831-8.

33. Murphy E., Cotter P., Hogan A. et al. Divergent metabolic outcomes arising from targeted manipulation of the gut microbiota in diet-induced obesity. Gut. 2013; Feb; 62(2):220-6.

34. Kadooka Y., Sato M., Imaizumi K. et al. Regulation of abdominal adiposity by probiotics (Lactobacillus gasseri SBT2055) in adults with obese tendencies in a randomized controlled trial. Eur J Clin Nutr. 2010; 64: 636-643.

35. Скворцов В. В. Дисбиоз кишечника и антибиотикоассоциированная диарея, диагностика и лечение. Лечащий врач. 2008; 2: 43-47.

36. Kinnear C.L., Strugnell R. A. Vaccination Method Affects Immune Response and Bacterial Growth but Not Protection in the Salmonella Typhimurium Animal Model of Typhoid. PLoS One. 2015; 10(10): e0141356

37. Zeng M., Mao X. H., Li J. X. et al. Efficacy, safety, and immunogenicity of an oral recombinant Helicobacter pylori vaccine in children in China: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015 Oct 10; 386(10002): 1457-64


Review

For citations:


Osadchuk A.M., Davydkin I.L., Gricenko T.A., Lebedeva E.A., Petrushin A.E. THE ROLE OF THE MICROBIOTA OF THE GASTROINTESTINAL TRACT IN THE DEVELOPMENT OF DISEASES OF INTERNAL ORGANS. Experimental and Clinical Gastroenterology. 2018;(5):133-139. (In Russ.)

Views: 313


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1682-8658 (Print)